Advertisement
-
-
Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease
An expert panel has proposed 28 recommendations for the design and conduct of clinical trials for alcohol use disorders and alcohol-associated liver disease. This field has a scarcity of clinical trials, despite alcohol abuse and alcohol-related liver disease being one of the greatest causes of morbidity and mortality worldwide.
-
-
MASLD/NAFLD
Fuelled by increasing obesity rates, metabolic dysfunction associated steatotic liver disease (MASLD, formerly known as NAFLD) has emerged as a leading global cause of chronic liver disease in the past few decades. Despite growing prevalence, the factors influencing MASLD development and subsequent progression to metabolic dysfunction associated steatohepatitis (MASH), liver fibrosis, cirrhosis and hepatocellular carcinoma are poorly understood. In this article series, Nature Reviews Gastroenterology & Hepatology explores the epidemiology of MASLD, disease mechanisms and therapeutics, and clinical approaches to diagnosis and management.
Trending - Altmetric
-
The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
-
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis
-
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
-
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement